ÄÚ³×ƼÄÆ ½ºÅÆÆ۵忡 ÀÖ´Â ·Ï¼Ò ¿ÂÄÝ·ÎÁö(Loxo Oncology)»çÀÇ ½Å¾à Larotrectinib (LOXO-101)°¡ TRK(Tropomyosin Receptor Kinase)' À¯ÀüÀÚ µ¹¿¬º¯ÀÌ º¸À¯ÇÑ ´Ù¾çÇÑ ¾Ï ȯÀÚ 4¸í Áß 3¸í¿¡°Ô ¹ÝÀÀÀ» º¸¿´´Ù´Â ÀÓ»ó°á°ú°¡ ¹ßÇ¥µÆ´Ù.
6ÀÏ(ÇöÁö½Ã°¢) Medscape ¿Í Targeted Oncology ¸Åü´Â ¹Ì±¹ÀÓ»óÁ¾¾çÇÐȸ(American Society of Clinical Oncology 2017 )¿¡¼ ¹ßÇ¥µÈ ÀÓ»ó°á°ú¸¦ Àοë, ÀÌ°°ÀÌ º¸µµÇß´Ù.
Larotrectinib ÀÓ»óÀ» ´ã´çÇÑ ¹Ì±¹ Memorial Sloan Kettering Cancer CenterÀÇ David Hyman ¹Ú»ç(»çÁø)´Â "Larotrectinib´Â °áÀå¾ÏºÎÅÍ Æó¾Ï, ÃéÀå¾Ï, °©»ó¼±¾Ï, Èæ»öÁ¾ µî¿¡ À̸£±â±îÁö 17°¡Áö¾Ï¿¡ ´ëÇØ Larotrectinib´Â 50¸í °¡¿îµ¥ 38¸í, Áï 76%ÀÇ È¯ÀÚ¿¡°Ô ¿¡°Ô ¹ÝÀÀÀ» º¸¿´´Ù. ÀÌ´Â ³î¶ó¿î °á°ú."¶ó°í ¼³¸íÇß´Ù.
À̵é ȯÀÚ´Â Larotrectinib Ä¡·á¸¦ ½ÃÀÛÇÑ µÚ 12°³¿ù° 79%ÀÇ È¯ÀÚ¿¡¼ ¹ÝÀÀÀÌ À¯ÁöµÇ°í ÀÖ´Ù.
Ä¡·á¹ÝÀÀÀÌ ÃÖÀå±â°£ À¯ÁöµÈ ȯÀÚÀÇ ±â·ÏÀº 25°³¿ù·Î ÇöÀç ÁøÇà ÁßÀÌ´Ù.
ÀÌµé ¸ðµÎ TRK À¯ÀüÀÚ µ¹¿¬º¯À̸¦ º¸À¯ÇÏ°í ÀÖ¾ú´Ù.
Loxo Oncology»ç´Â À̹ø ±àÁ¤ÀûÀÎ ÀÓ»ó°á°ú¸¦ ¹ÙÅÁÀ¸·Î 2017³â ÈĹÝÀ̳ª 2018³â ÃÊ¿¡ FDA ½ÂÀÎ ½ÅûÀ» ÇÒ ¿¹Á¤À̶ó°í ¹àÇû´Ù.
¿ø¹®ÂüÁ¶.
http://www.targetedonc.com/conference/asco-2017/responses-stimulated-across-all-tumor-types-harboring-trk-fusions-with-larotrectinib